Core Insights - Bright Peak Therapeutics has appointed John Schmid to its Board of Directors, bringing extensive experience in the biotechnology sector [1][2] - Schmid has over 35 years of financial and senior management experience, having raised over $900 million through various financing methods [2][4] - The company is focused on developing multifunctional immunotherapies for cancer, with its lead program BPT567 currently in Phase 1/2a clinical trials [5] Company Overview - Bright Peak Therapeutics is a clinical-stage biotechnology company specializing in multifunctional immunotherapies for cancer [5] - The company utilizes innovative protein engineering and a proprietary chemical conjugation platform to develop its pipeline [5] - Bright Peak operates from dual locations in San Diego, California, and Basel, Switzerland [5] Leadership and Experience - John Schmid has a proven track record, having guided two companies through successful IPOs and participated in six additional IPOs as an independent board member [2][4] - His previous roles include CFO of Auspex Pharmaceuticals, which went public in 2014 and was sold to Teva for $3.5 billion, and co-founder of Trius Therapeutics, acquired for over $700 million [4] - Schmid currently serves on the boards of several biotechnology companies and acts as Audit Chair for each [3]

AnaptysBio, Inc. (ANAB) shares rallied 9.5% in the last trading session to close at $18.71. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 8.1% loss over the past four weeks.The stock rallied after the company announced that the board of directors has authorized a stock repurchase plan under which it may repurchase up to $75,000,000 of the outstanding common stock, par value $0.001 per share.This company is ...

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company’s outstanding common stock, par value $0.001 per share. Anaptys has cash, cash equivalents and investments greater than $420 million as of December 31, 2024, and anticipates receipt ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-K ______________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-37985 ______________________________________ ANAPTYSBIO, INC. (Ex ...

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update SAN DIEGO, Feb. 27, 2025 — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a business update. "Rosnilimab's positive Phase 2b data in rheumatoid arthritis has revealed impressive safety, tolerability and three-month efficacy dat ...

SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: TD Cowen 45th Annual Healthcare Conference, Boston, MA Format – Fireside chat and one-on-one investor meetingsDate and Time – ...

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and translational data for rosnilimab in RA in Q2 2025Top-line Phase 2 data for rosnilimab in ulcerative colitis (UC), moved up to Q4 2025Phase 1a trial in healthy volunteers ongoing for ANB033, our CD122 antagonist, and Phase 1a trial to initiate this quarter for ANB101, our BDCA2 modulatorAnnounced exclusive global ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has AnaptysBio, Inc. (ANAB) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.AnaptysBio, Inc. is one of 1010 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 diff ...

AnaptysBio, Inc. (ANAB) shares rallied 30.5% in the last trading session to close at $16.15. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 17% loss over the past four weeks.The stock price soared after AnaptysBio announced meeting the primary endpoint in a mid-stage study of its investigational candidate, rosnilimab, for moderate-to-severe rheumatoid arthritis (RA) across all three doses compared to placebo ...

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placeboAchieved statistical significance on key secondary endpoints at Week 12 on ACR20, ACR50 and CDAI LDADemonstrated highest ever reported responses on key secondary endpoints at Week 14 on ACR20, ACR50, ACR70 and CDAI LDA69% of rosnilimab-treated patients achieved CDAI LDA at Week 14 and appear to show sustained CDAI LDA and ACR50 responses and potentially deepening AC ...